Introduction and Objectives Existing HRQoL scales have poor content validity for severe asthma as they fail to measure the qualitatively different burdens experienced by the severe asthma population compared to those with mild or moderate asthma, in particular, the side effects of oral corticosteroids (OCS). A new severe asthma quality of life questionnaire (SAQ) has been designed using extensive patient input in qualitative studies as per FDA guidelines. The questionnaire has 16 questions rated on a 1-7 Likert scale and a 100 point global quality of life scale (GQoL) similar to the EQ-5Ds 100 point visual analogue scale (VAS) (SAQ.org.uk). Methods Consecutive consenting patients attending the severe asthma clinic in Plymouth with severe asthma were invited to participate in a cross sectional survey. Patients completed four questionnaires the SAQ, mini Asthma Quality of Life Questionnaire (miniAQLQ), Asthma Control Test (ACT) and the EQ-5D. Prednisolone dose and frequency of severe exacerbations were obtained from clinic records. Results 102 participants (64 female, mean age=51 years range 18-79 years), of whom 38 were on maintenance OCS consented to take part, mean FEV1% of 69%. Correlations between the four questionnaires were all above 0.65. Correlations with frequency of severe exacerbations were SAQ 0.31, miniAQLQ 0.31, ACT 0.34. The SAQ's GQoL correlated with the EQ-5D's VAS at 0.73. The SAQ was significantly better than the miniAQLQ at predicting the quality of life of patients taking 10 mg OCS a day (p<0.05 vs p=0.88). These questionnaires had parallel Results for doses up to 10 mg but above that only SAQ provided differentiation between patients. Conclusions Preliminary Results indicate that the SAQ may be a more valid measure of quality of life in severe asthma than existing questionnaires. The SAQ maps onto a pre-existing health economic measure, the EQ-5D. Furthermore the SAQ has greater sensitivity to differences in OCS dose compared to the AQLQ. The SAQ will be assessed further in a larger validation study. The Improving Asthma Care Together (ImpACT) project implements a novel model of care which provides an integrated responsive services for asthma patients in Derby. Aim The hypothesis of this project was that rapid review by a specialist asthma nurse in the community during an asthma exacerbation, would result in an improvement in patient's asthma control and their ability to self-manage their asthma. Methods Four specialist asthma nurses were recruited to provide seven day cover for the service. Patients who reported increasing asthma symptoms could access the service by selfreferral or referral from a healthcare professional. The intervention involved a face-to-face review or a telephone call from a specialist asthma nurse. Patients were offered a 30 min face to face review at a variety of GP locations in the region. A template for each ImpACT review was constructed and a management plan issued at each consultation. A questionnaire was devised and patients were asked to complete this approximately 6 weeks following the intervention. A 10 point scale was used to ask patient's what their confidence levels were in self-managing their asthma (0=no confidence and 10=highly confident) and how they rated their asthma control (0=poor and 10=excellent). Results This project commenced in January 2017. Between the start date and June 2017 a total of 884 patients were reviewed as part of the service. 397 face-to-face visits, 470 telephone consultations and 17 home visits. Patient's self-rating of their asthma control significantly improved following the intervention (pre-intervention mean 3. Introduction and Objectives Blood eosinophil counts (Bl-Eos) and fractional exhaled nitric oxide concentrations (FeNO) are established biomarkers in asthma. While patients with raised Bl-Eos are at increased risk of asthma exacerbations, it is unclear whether raised FeNO is associated with further increased risk. We sought to determine if raised Bl-Eos combined with raised FeNO was associated with increased frequency of asthma exacerbations. Methods This was a cross-sectional study of data from the Optimum Patient Care Research Database. Patients included were aged 18-80 years with 1 year of continuous electronic health records prior to their most recent FeNO readings, had evidence of asthma, had received 1 inhaled corticosteroid prescription, and had Bl-Eos recorded within 5 years of FeNO reading. Cohorts were determined by: Bl-Eos raised (0.25×10 9 /L, a cutoff representing the sample mean) and not raised (<0.25×10 9 /L) and, FeNO raised (35 ppb) and not raised (<35 ppb). Patients were directly matched on age, sex, and smoking status. Patients with (i) raised Bl-Eos and not raised FeNO, (ii) raised FeNO and not raised Bl-Eos, or (iii) both biomarkers raised were compared with reference patients (neither biomarker raised). Comparison of exacerbations (evidenced by acute oral corticosteroid prescription or unplanned asthma-related hospital attendance) was conducted using conditional Poisson regression. Results The unmatched study population consisted of 610 patients (mean age 52, 38% male, 46% non-smokers). Background and Objectives Previous studies have linked oral corticosteroid use in asthma patients to various adverse events. This study aimed to assess in more depth than has previously been done the toxicity profile of oral prednisolone among adult asthma patients. Methods Using data from the UK-based Clinical Practice Research Datalink, we conducted a series of cohort studies, each with a nested case-control analysis, to quantify the risk of 11 different potential corticosteroid-related adverse events. Results Incidence rates per 1000 person-years of potential corticosteroid-related adverse events in patients with new current use of oral prednisolone ranged from 1.4 (95% confidence interval [CI], 1.0-1.8) for peptic ulcer to 78.0 (95% CI, 74.8-81.2) for severe infections. After adjusting for confounding, current oral prednisolone use was most strongly associated with an increased risk of severe infection (odds ratio [OR] 2.16; 95% CI, 2.05-2.27) compared with non-use of prednisolone. There were smaller elevated risks of peptic ulcer (OR 1.47; 95% CI, 1.12-1.92), affective disorders (OR 1.47; 95% CI, 1.32-1.63), herpes zoster (OR 1.32; 95% CI 1.19-1.48), cardiovascular events (OR 1.33; 95% CI 1.18-1.49), diabetes mellitus type 2 (OR 1.35; 95% CI 1.22-1.49), bone related conditions (OR 1.27; 95% CI 1.17-1.37), and cataract at higher cumulative doses (cumulative dose 2000 mg: OR 1.43; 95% CI 1.17-1.73), compared with non-use of prednisolone. We did not observe an association between current oral prednisolone use and glaucoma, chronic kidney disease, or hypertension. Past use of oral prednisolone was not associated with any of the study outcomes. We observed possible doseresponse relationships between current oral prednisolone use and the risk of cardiovascular events, affective disorders, bone-related conditions, severe infections, diabetes mellitus type 2, and cataract, but not the other investigated outcomes. Conclusion Oral prednisolone use is associated with an increased risk of infections, gastrointestinal, neuropsychiatric, ocular, cardiovascular, metabolic, and bone-related complications among adult asthma patients. The risk is associated with current but not past use of oral prednisolone use, and for some outcomes with the prescribed dose of oral prednisolone. The calculation of the cost-saving for the NHS was estimated for a population of 1,000 asthma patients.
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